Cargando…
Niacin Extended Release (ER)/Simvastatin (Simcor®): A Guide to its Use in Lipid Regulation
Oral fixed-dose niacin extended release/simvastatin is associatedwith clinically relevant improvements in plasma lipid profiles, including lowering of nonhigh- density lipoprotein cholesterol levels, relative to simvastatinmonotherapy in patients with mixed dyslipidemias who had not responded fully...
Autor principal: | Lyseng-Williamson, Katherine A. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3586144/ https://www.ncbi.nlm.nih.gov/pubmed/21171671 http://dx.doi.org/10.2165/11202560-000000000-00000 |
Ejemplares similares
-
Management of complex lipid abnormalities with a fixed dose combination of simvastatin and extended release niacin
por: Robinson, Jennifer G
Publicado: (2009) -
Pentoxifylline and its applications in dermatology
por: Hassan, Iffat, et al.
Publicado: (2014) -
Targeting mulitple dyslipidemias with fixed combinations – focus on extended release niacin and simvastatin
por: Pandian, Anbu, et al.
Publicado: (2008) -
Combination of niacin extended-release and simvastatin results in a less atherogenic lipid profile than atorvastatin monotherapy
por: Insull, William, et al.
Publicado: (2010) -
Anakinra in Still’s disease: a profile of its use
por: Lyseng-Williamson, Katherine A.
Publicado: (2018)